

Weekly First Approvals of New Drugs

Sep. 16th 2024

1. Ocrelizumab/Hyaluronidase

FDA Approval Date: Sep. 13th, 2024

Brand name: Ocrevus Zunovo

Indication: Multiple sclerosis

Mechanism: CD20-directed cytolytic effects

Dosage form: Injection

Company: Genentech



Ocrevus Zunovo, developed based on Ocrevus, is a subcutaneous injection that offers the advantage of being administered in just 10 minutes and only requires two injections per year, providing great convenience for patients.



2. atezolizumab/hyaluronidase-tqjs

FDA Approval Date: Sep. 12th, 2024

Brand name: Tecentriq Hybreza

Mechanism: Hyaluronic acid modulators
/PDL1 inhibitors

Dosage form: Injection

Company: Genentech

Tecentriq Hybreza is suitable for all adult indications approved by the FDA for Tecentriq intravenous injections, covering lung cancer, bladder cancer, breast cancer, and liver cancer.

3. Stapokibart

NMPA Approval Date: Sep. 10th, 2024

Brand name: 康悦达

Indication: Dermatitis, Atopic

Mechanism: IL-4R α inhibitors

Dosage form: Injection

Company: Keymed Biosciences



Stapokibart is a high-affinity, humanized antibody targeting IL-4R α , developed by Keymed Biosciences. By targeting IL-4R α , it dual blocks the signaling of IL-4 and IL-13, thereby inhibiting inflammatory responses. It is used for indications such as moderate to severe asthma, COPD (Chronic Obstructive Pulmonary Disease), and atopic dermatitis.